Related Experiment Videos
[Physical dependence liability test of 4-(o-benzylphenoxy)-N-methylbutylamine hydrochloride (MCI-2016) in rats]
Abstract:
An acute administration of MCI-2016 at the doses of 30, 100 and 300 mg/kg (p.o.), and 10, 20 and 30 mg/kg (i.p.) produced a slight CNS depression in rats, such as, sedation, ptosis, decrease in motor activity and systemic muscle relaxation. In a direct physical dependence test, rats were fed the MCI-2016-admixed food together with drinking water ad libitum for 24 hours daily for 51-71 days (mean MCI-2016 intake 29.9-210.7 mg/kg/day), on the gradedly increased dosage schedule with a dosage level of 0.25 and 0.5 mg/g food to 4 mg/g food. In a natural withdrawal following administration of MCI-2016, no significant withdrawal signs were observed in any group. In a naloxone-precipitation test the rats that were treated with MCI-2016-admixed food did not show any withdrawal signs. In a substitution test in either morphine or barbital dependent rats, no suppression of withdrawal signs or maintenance of dependence were observed by cross-administration of MCI-2016. In conclusion, MCI-2016 was considered to have no physical dependence potential.
Insights
MCI-2016 administration showed mild central nervous system depression in rats. Crucially, this compound demonstrated no evidence of physical dependence potential in multiple rigorous testing protocols.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Dependence Research
Background:
- Investigating the pharmacological profile of novel compounds is essential for understanding their therapeutic potential and safety.
- The potential for a drug to induce physical dependence is a critical factor in its clinical utility and regulatory assessment.
Purpose of the Study:
- To evaluate the acute central nervous system (CNS) effects of MCI-2016 in a rodent model.
- To assess the physical dependence potential of MCI-2016 through direct dependence, naloxone-precipitated, and substitution tests.
Main Methods:
- Acute CNS effects were assessed following oral (p.o.) and intraperitoneal (i.p.) administration of MCI-2016 in rats.
- Physical dependence was evaluated over 51-71 days using admixed food and water, followed by natural and naloxone-precipitated withdrawal assessments.
- Substitution tests were conducted in morphine- or barbital-dependent rats to assess cross-dependence.
Main Results:
- Acute MCI-2016 administration (30-300 mg/kg p.o., 10-30 mg/kg i.p.) resulted in mild CNS depression, including sedation and decreased motor activity.
- No significant withdrawal signs were observed in any group during natural withdrawal or after naloxone challenge.
- MCI-2016 did not suppress withdrawal signs or maintain dependence in morphine- or barbital-dependent rats.
Conclusions:
- MCI-2016 exhibits mild CNS depressant effects upon acute administration.
- The compound does not appear to induce physical dependence, as evidenced by the lack of withdrawal signs and negative substitution test results.
- MCI-2016 is considered to have no physical dependence potential.